Iranian Journal of Radiology

Published by: Kowsar

Outcomes of Transarterial Chemoembolization With or Without Additional Radiofrequency Ablation in Hepatocellular Carcinoma of 2 to 5 cm in Diameter

Mi-Young Kim 1 , Jin Woong Kim 2 , Dae-Seong Myung 1 , Chung-Hwan Jun 1 , Wan-Sik Lee 1 , Yang Jun Kang 2 , Sung-Kyu Choi 1 , Young-Eun Joo 1 and Sung-Bum Cho 1 , *
Authors Information
1 Departments of Internal Medicine, Chonnam National University Medical School, Gwangju, Korea
2 Departments of Radiology, Chonnam National University Medical School, Gwangju, Korea
Article information
  • Iranian Journal of Radiology: January 2017, 14 (1); e13484
  • Published Online: October 4, 2016
  • Article Type: Research Article
  • Received: June 11, 2016
  • Revised: August 4, 2016
  • Accepted: August 15, 2016
  • DOI: 10.5812/iranjradiol.39515

To Cite: Kim M, Kim J W, Myung D, Jun C, Lee W, et al. Outcomes of Transarterial Chemoembolization With or Without Additional Radiofrequency Ablation in Hepatocellular Carcinoma of 2 to 5 cm in Diameter, Iran J Radiol. 2017 ; 14(1):e13484. doi: 10.5812/iranjradiol.39515.

Abstract
Copyright © 2016, Tehran University of Medical Sciences and Iranian Society of Radiology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379(9822): 1245-55[DOI][PubMed]
  • 2. Santi V, Trevisani F, Gramenzi A, Grignaschi A, Mirici-Cappa F, Del Poggio P, et al. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol. 2010; 53(2): 291-7[DOI][PubMed]
  • 3. Takaki H, Yamakado K, Sakurai H, Nakatsuka A, Shiraki K, Isaji S, et al. Radiofrequency ablation combined with chemoembolization: treatment of recurrent hepatocellular carcinomas after hepatectomy. AJR Am J Roentgenol. 2011; 197(2): 488-94[DOI][PubMed]
  • 4. Kim JW, Shin SS, Kim JK, Choi SK, Heo SH, Lim HS, et al. Radiofrequency ablation combined with transcatheter arterial chemoembolization for the treatment of single hepatocellular carcinoma of 2 to 5 cm in diameter: comparison with surgical resection. Korean J Radiol. 2013; 14(4): 626-35[DOI][PubMed]
  • 5. Kirikoshi H, Saito S, Yoneda M, Fujita K, Mawatari H, Uchiyama T, et al. Outcome of transarterial chemoembolization monotherapy, and in combination with percutaneous ethanol injection, or radiofrequency ablation therapy for hepatocellular carcinoma. Hepatol Res. 2009; 39(6): 553-62[DOI][PubMed]
  • 6. Buscarini L, Buscarini E, Di Stasi M, Quaretti P, Zangrandi A. Percutaneous radiofrequency thermal ablation combined with transcatheter arterial embolization in the treatment of large hepatocellular carcinoma. Ultraschall Med. 1999; 20(2): 47-53[DOI][PubMed]
  • 7. Peng ZW, Zhang YJ, Chen MS, Xu L, Liang HH, Lin XJ, et al. Radiofrequency ablation with or without transcatheter arterial chemoembolization in the treatment of hepatocellular carcinoma: a prospective randomized trial. J Clin Oncol. 2013; 31(4): 426-32[DOI][PubMed]
  • 8. Kim JH, Won HJ, Shin YM, Kim SH, Yoon HK, Sung KB, et al. Medium-sized (3.1-5.0 cm) hepatocellular carcinoma: transarterial chemoembolization plus radiofrequency ablation versus radiofrequency ablation alone. Ann Surg Oncol. 2011; 18(6): 1624-9[DOI][PubMed]
  • 9. Azuma S, Asahina Y, Nishimura-Sakurai Y, Kakinuma S, Kaneko S, Nagata H, et al. Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma. Hepatol Res. 2016; 46(4): 312-9[DOI][PubMed]
  • 10. European Association For The Study Of The L, European Organisation For R, Treatment Of C. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012; 56(4): 908-43[DOI][PubMed]
  • 11. Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010; 4(2): 439-74[DOI][PubMed]
  • 12. Forner A, Reig ME, de Lope CR, Bruix J. Current strategy for staging and treatment: the BCLC update and future prospects. Semin Liver Dis. 2010; 30(1): 61-74[DOI][PubMed]
  • 13. Xu LF, Sun HL, Chen YT, Ni JY, Chen D, Luo JH, et al. Large primary hepatocellular carcinoma: transarterial chemoembolization monotherapy versus combined transarterial chemoembolization-percutaneous microwave coagulation therapy. J Gastroenterol Hepatol. 2013; 28(3): 456-63[DOI][PubMed]
  • 14. Ni JY, Liu SS, Xu LF, Sun HL, Chen YT. Transarterial chemoembolization combined with percutaneous radiofrequency ablation versus TACE and PRFA monotherapy in the treatment for hepatocellular carcinoma: a meta-analysis. J Cancer Res Clin Oncol. 2013; 139(4): 653-9[DOI][PubMed]
  • 15. Wang Y, Deng T, Zeng L, Chen W. Efficacy and safety of radiofrequency ablation and transcatheter arterial chemoembolization for treatment of hepatocellular carcinoma: A meta-analysis. Hepatol Res. 2016; 46(1): 58-71[DOI][PubMed]
  • 16. Kim JW, Kim JH, Won HJ, Shin YM, Yoon HK, Sung KB, et al. Hepatocellular carcinomas 2-3 cm in diameter: transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone. Eur J Radiol. 2012; 81(3): 189-93[DOI][PubMed]
  • 17. Komorizono Y, Oketani M, Sako K, Yamasaki N, Shibatou T, Maeda M, et al. Risk factors for local recurrence of small hepatocellular carcinoma tumors after a single session, single application of percutaneous radiofrequency ablation. Cancer. 2003; 97(5): 1253-62[DOI][PubMed]
  • 18. Buscarini E, Savoia A, Brambilla G, Menozzi F, Reduzzi L, Strobel D, et al. Radiofrequency thermal ablation of liver tumors. Eur Radiol. 2005; 15(5): 884-94[DOI][PubMed]
  • 19. Morimoto M, Numata K, Kondou M, Nozaki A, Morita S, Tanaka K. Midterm outcomes in patients with intermediate-sized hepatocellular carcinoma: a randomized controlled trial for determining the efficacy of radiofrequency ablation combined with transcatheter arterial chemoembolization. Cancer. 2010; 116(23): 5452-60[DOI][PubMed]
  • 20. Takaki H, Yamakado K, Nakatsuka A, Fuke H, Murata K, Shiraki K, et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas 5 cm or smaller: risk factors for local tumor progression. J Vasc Interv Radiol. 2007; 18(7): 856-61[DOI][PubMed]
  • 21. Morimoto M, Sugimori K, Shirato K, Kokawa A, Tomita N, Saito T, et al. Treatment of hepatocellular carcinoma with radiofrequency ablation: radiologic-histologic correlation during follow-up periods. Hepatology. 2002; 35(6): 1467-75[DOI][PubMed]
  • 22. Shibata T, Isoda H, Hirokawa Y, Arizono S, Shimada K, Togashi K. Small hepatocellular carcinoma: is radiofrequency ablation combined with transcatheter arterial chemoembolization more effective than radiofrequency ablation alone for treatment? Radiology. 2009; 252(3): 905-13[DOI][PubMed]
  • 23. Georgiades CS, Hong K, Geschwind JF. Radiofrequency ablation and chemoembolization for hepatocellular carcinoma. Cancer J. 2008; 14(2): 117-22[DOI][PubMed]
  • 24. Zhu AX, Abou-Alfa GK. Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation. JAMA. 2008; 299(14): 1716-8[DOI][PubMed]
  • 25. Takaki H, Yamakado K, Uraki J, Nakatsuka A, Fuke H, Yamamoto N, et al. Radiofrequency ablation combined with chemoembolization for the treatment of hepatocellular carcinomas larger than 5 cm. J Vasc Interv Radiol. 2009; 20(2): 217-24[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments